Breast cancer: The second leading cause of cancer death in women

In the United States, breast cancer is the second leading cause of cancer death in women and only 1 in 4 diagnosed with metastases will reach 5-year survival.1,2

Indoximod is being studied in metastatic breast cancer3

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.4,5

Learn about the IDO pathway and IDO pathway inhibitors

Learn more about the indoximod study in metastatic breast cancer



1. Centers for Disease Control and Prevention. Cancer among women. Updated August 20, 2015. Accessed October 3, 2015. 2. National Cancer Institute. SEER stat fact sheets: breast cancer. Accessed October 4, 2015. 3. National Institutes of Health. Study of chemotherapy in combination with IDO inhibitor in metastatic breast cancer. . Accessed October 4, 2015. 4. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 5. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.